

Department of Radiation Oncology

Monthly Research Update: June 2026

NIH Proposes Cap on Grants Per PI/MPI

JUNE AT A GLANCE TOTALS

Clinical trials

Total enrolled	33
GCC, other	10
NRG, co-ops	7
PCG, other registries	16

Grants and contracts

New awards	1
Submitted	1

Articles published	4
--------------------	---

August 3 is the deadline for submission of comments to NIH on a [proposed policy](#) that would cap the number of Research Project Grants (RPGs) on which an individual can simultaneously serve as principal investigator (PI) or multi-principal investigator (MPI). RPGs constitute most of the familiar NIH mechanisms, including R01, R21, U awards, and many others. NIH stated that the policy is intended to support “a greater number of investigators, allowing more ideas to be explored and eventually leading to more breakthroughs.” The number of grants to be capped has not been determined, but examples cited included caps of 2-4 RPGs per PI or MPI. Implementation considerations provided by NIH outlined a complex process by which PIs or multi-PIs at the cap would have to give up an existing grant or transfer PI status to another researcher in order to secure a new award or renewal. Grantee institutions would bear the responsibility for monitoring the caps and planning for such transitions. The proposal has met with considerable pushback from senior researchers and their institutions, with concerns about effects on large projects, clinical trials, and other investigations. More information about the proposal is available at NIH, and a form for submitting comments is included on the same [page](#).

Clinical Trial Enrollment

Information for this monthly update should be provided no later than the second Wednesday of each month to Miek Segers at msegers@som.umaryland.edu. The update will be published on the second Friday of each month.

Have questions about identifying a funding source? Finding research partners across the UMB/UM campuses or at another university? Defining future research strategies? Or organizing your thoughts on (virtual) paper? Contact Nancy Knight, PhD, Director of Academic and Professional Development for the department, at nknight@umm.edu.

- 16 patients at MPTC on the **Proton Collaborative Group Registry**
- 1 patient at MPTC, 1 at BWMC, 1 at Shore, and 2 at UCH on **NRG GU013**: The phase III 'High Five Trial' five fraction radiation for high-risk prostate cancer
- 1 patient at UMMC on **GCC 2380**: A single arm phase I-II trial evaluating selective adjuvant therapy for HPV-mediated oropharynx SCCs based on residual circulating tumor DNA (ctDNA) levels (SAVAL)
- 2 patients at UMMC on **GCC 2422**: Phase I feasibility and pilot RCT of serious illness conversation guide in patient and intimate partner dyads living with advanced lung cancer
- 1 patient at MPTC and 1 at UCH on **GCC 2563/PCG BRE009**: Phase III randomized trial of conventionally fractionated vs. hypo fractionated comprehensive nodal irradiation for breast cancer using pencil beam scanning protons therapy (COMPRO)
- 1 patient at MPTC on **GCC 2431**: A pilot study of systemic immune-based therapy combined with hyperthermia and spatially fractionated radiotherapy in advanced biliary tract cancer and hepatocellular carcinoma
- 1 patient at UMMC on **GCC 2494**: Practical clinical interventions to help improve cancer care for patients who live in food priority areas (FPAs) or food deserts.
- 1 patient at UMMC on **GCC 21136**: Phase 2 randomized total eradication of metastatic lesions following definitive radiation to the prostate in de novo oligometastatic prostate cancer (TERPS) trial
- 2 patients at MPTC on **GCC 2032**: Feasibility of strength training with androgen deprivation and proton therapy for high-risk prostate cancer
- 2 patients at UCH on **GCC 1926**: A phase I dose escalation study of single fraction pre-operative partial breast S-PBI for early-stage breast cancer

Grants and Contracts

Funded

- **Mark Mishra, MD, PI**, RTOG Foundation, “3543 Study: MOMENTUM-1: A multicenter, randomized, open-label, phase II study of [¹⁷⁷Lu]Lu-DOTATATE in adults with progressive intracranial grade 1-3 meningioma” (\$235,999) (6/8/2026–6/7/2031).

Submitted

- **Yannick Poirier, PhD, PI**, Pacific Northwest National Lab (PNNL) op. Battelle Memorial Inst/ Department of Energy, “RFP 951918: Cesium irradiator replacement project (CIRP)” (\$449,705).

Articles Published

Entered into PubMed June 11 through July 9. Titles link to PubMed abstracts.

1. Bentzen SM, Gupta T, Jacinto AA, Rosenblatt E, Bhasker S, Napoles M, Binia S, Chansilpa Y, Aguiar S, Nagarajan M, Laskar SG, De Marchi P, Goloubeva O, Hopkins K, Zubizarreta E, Agarwal JP, Abdel-Wahab M. [In reply to Acharya. Int J Radiat Oncol Biol Phys.](#) 2026 Jul 15;125(4):1285-1286.
2. Biswal NC, Chheng HR, Parchur AK, Zhang B, Alicia D, Manuel E, Sun K, Yi B, Ferris MJ, Rana Z. [Predictive dosimetric parameters for adaptive replanning in proton beam therapy for thoracic cancer. Med Dosim.](#) 2026 Jul 4:S0958-3947(26)00050-6. Online ahead of print.
3. Moradmamand H, Molitoris J, Mehra R, Schumaker L, Allor E, Gaykalova DA, Ren L. [Impact of radiomics parameters and clinical integration on prognostication in head and neck squamous cell carcinoma: A multicenter study. Life \(Basel\).](#) 2026 Jun 19;16(6):1027.
4. Schreck KC, de la Fuente MI, Fat MJL, Maas SLN, Mulcahy Levy JM, Lombardi G, Perrault S, Petritsch CK, Aldape K, Chang SM, Duerinck J, Holdhoff M, Kazda T, Rhun EL, Minniti G, Mishra MV, Mueller S, Padovan M, Preusser M, Smits M, Weller M, Wen PY, van den Bent M, Geurts M. [BRAF-altered glioma in adults and children: A Society for Neuro-Oncology \(SNO\) and European Society for Neuro-Oncology \(EANO\) consensus review on clinical management and future directions. Neuro Oncol.](#) 2026 Jun 8:noag135. Online ahead of print.

Important Dates for Upcoming Funding Submissions

Below is an updated calendar for **near-term NIH Submission Deadlines for 2026**, with firm due dates for major standard NIH deadlines (RFA/PA dates may differ). Contact the Department Office of Research Administration (msegers@som.umaryland.edu) ASAP if you plan to submit a proposal, regardless of funder.

NIH deadline ⁴	DORA deadline ¹	ORA deadline ²	SPA deadline ³
R01 Oct 5 (new)	09/21/2026	09/24/2026	09/28/2026
*R21 Oct 16 (new)	10/02/2026	10/07/2026	10/09/2026
R01 Nov 5 (Resub)	10/22/2026	10/27/2026	10/29/2026
*R21 Nov 16 (Resub)	11/02/2026	11/05/2026	11/09/2026

¹DORA deadline: All forms to be included in proposal, known or in draft, budget final, subcontractor budgets and information final in final form, 9 business day prior to NIH deadline. ²ORA deadline: Personnel, effort, budget materials, performance site, and compliance forms routed in final form, 7 business days prior to NIH deadline. ³SPA deadline: All proposal materials routed in FINAL form by 5 pm, 5 business days prior to NIH deadline. No more corrections allowed, unless indicated after review by SPA. *R21 deadline is also for R03, R33, R21/R33, R34, R36, U34, UH2, UH3, and UH2/UH3 submissions.